Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1SQSE)

• Drug Name: ICLUSIG Drug Info
• Synonyms: Ponatinib hydrochloride; 1114544-31-8; Ponatinib HCl; Iclusig; AP 24534 hydrochloride; AP24534 HCL; Ponatinib Mono-hydrochloride; UNII-96R6PU3D8J; 96R6PU3D8J; Ponatinib hydrochloride [USAN]; AP-24534 HCl; Ponatinib (hydrochloride); AP-24534 hydrochloride; CHEBI:191940; DTXSID50149655; 1114544-31-8 (HCl); 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide hydrochloride; 3-(2-(Imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1- yl)methyl)-3-(trifluoromethyl)phenyl)benzamide monohydrochloride; Benzamide, 3-(2-imidazo(1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methyl-1- piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-, hydrochloride (1:1); C29H28ClF3N6O; 3-((imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide--hydrogen chloride; 3-(2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl)benzamide hydrochloride; 3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide hydrochloride; 3-(imidazo(1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide hydrochloride; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide hydrochloride; 3-[(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide--hydrogen chloride; 4-((4-(3-((imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methylbenzamido)-2-(trifluoromethyl)phenyl)methyl)-1-methylpiperazin-1-ium chloride; 4-(4-(3-(imidazo(1,2-b)pyridazin-3-ylethynyl)-4-methylbenzamido)-2-(trifluoromethyl)benzyl)-1-methylpiperazin-1-ium chloride; 4-{[4-{3-[(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methylbenzamido}-2-(trifluoromethyl)phenyl]methyl}-1-methylpiperazin-1-ium chloride; 4-{4-[3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamido]-2-(trifluoromethyl)benzyl}-1-methylpiperazin-1-ium chloride; Iclusig (TN); Ponatinib (HCl salt); Ponatinib (2 x HCl Salt); AMY367; AP 24534 HCl; CHEMBL2105708; DTXCID0072146; SCHEMBL15798559; 943319-70-8 free base; BCP10906; Ponatinib hydrochloride (JAN/USAN); PONATINIB HYDROCHLORIDE [MI]; EX-A067-1; PONATINIB HYDROCHLORIDE [JAN]; AKOS030621539; PONATINIB HYDROCHLORIDE [WHO-DD]; AC-32047; AS-16772; HY-108766; CS-0031009; PONATINIB HYDROCHLORIDE [ORANGE BOOK]; D09951; Q27271925; 3-(2-(Imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide monohydrochloride; 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide;hydrochloride; Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1-Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)-, Hydrochloride (1:1)

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 46908927
  TTD Drug ID: DM1SQSE

Molecule-Related Drug Atlas

Drug(s) Targeting Fusion protein Bcr-Abl (Bcr-Abl)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[3]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Asciminib	DM7EVUF	Chronic myeloid leukaemia	2A20	Approved	[5]
Radotinib	DMWA74Y	leukaemia	2A60-2B33	Phase 3	[6]
ABL 001	DMMF5K4	Chronic myeloid leukaemia	2A20	Phase 3	[7]
Bafetinib	DM7586F	Bone disease	FC0Z	Phase 2	[8]
AN-019	DMJ7QP8	Chronic myelogenous leukaemia	2A20.0	Phase 2	[9]
HQP1351	DMQ30X2	Chronic myeloid leukaemia	2A20	Phase 2	[10]
NPB-001-056	DM78KMT	Chronic myelogenous leukaemia	2A20.0	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03589326) A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). U.S.National Institutes of Health.
• [2] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404.
• [3] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [4] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [5] Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
• [6] Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
• [7] ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
• [8] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [9] Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
• [10] Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
• [11] NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88.